These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 19616848)

  • 21. Bcl-2 gene rearrangement in Jordanian follicular and diffuse large B-cell lymphomas.
    Almasri NM; Al-Alami J; Faza M
    Saudi Med J; 2005 Feb; 26(2):251-5. PubMed ID: 15770300
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rapid and reliable quantification of minimal residual disease in acute lymphoblastic leukemia using rearranged immunoglobulin and T-cell receptor loci by LightCycler technology.
    Nakao M; Janssen JW; Flohr T; Bartram CR
    Cancer Res; 2000 Jun; 60(12):3281-9. PubMed ID: 10866322
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bone marrow minimal disseminated disease (MDD) and minimal residual disease (MRD) in childhood T-cell lymphoblastic lymphoma stage III, detected by flow cytometry (FC) and real-time quantitative polymerase chain reaction (RQ-PCR).
    Stark B; Avigad S; Luria D; Manor S; Reshef-Ronen T; Avrahami G; Yaniv I
    Pediatr Blood Cancer; 2009 Jan; 52(1):20-5. PubMed ID: 19006253
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fluorescent polymerase chain reaction and capillary electrophoresis for IgH rearrangement and minimal residual disease evaluation in multiple myeloma.
    Novella E; Giaretta I; Elice F; Madeo D; Piccin A; Castaman G; Rodeghiero F
    Haematologica; 2002 Nov; 87(11):1157-64. PubMed ID: 12414345
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inactivation of p57KIP2 by regional promoter hypermethylation and histone deacetylation in human tumors.
    Kikuchi T; Toyota M; Itoh F; Suzuki H; Obata T; Yamamoto H; Kakiuchi H; Kusano M; Issa JP; Tokino T; Imai K
    Oncogene; 2002 Apr; 21(17):2741-9. PubMed ID: 11965547
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gene amplification of Japanese non-Hodgkin lymphoma with involvement of the BCL2 gene.
    Miyamura K; Kobayashi T; Sasaki T; Ibuka T; Imai K; Sakai Y; Kawaguchi K; Miyashita T; Iwaya M; Mizutani S
    Int J Hematol; 1991 Apr; 54(2):137-40. PubMed ID: 1747446
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differential response to H. pylori eradication therapy of co-existing diffuse large B-cell lymphoma and MALT lymphoma of stomach-significance of tumour cell clonality and BCL10 expression.
    Kuo SH; Chen LT; Wu MS; Kuo KT; Yeh KH; Doong SL; Yeh PY; Hsu HC; Tzeng YS; Lin CW; Lin JT; Cheng AL
    J Pathol; 2007 Feb; 211(3):296-304. PubMed ID: 17167822
    [TBL] [Abstract][Full Text] [Related]  

  • 28. BCL2 gene aberration as an IPI-independent marker for poor outcome in non-germinal-centre diffuse large B cell lymphoma.
    Obermann EC; Csato M; Dirnhofer S; Tzankov A
    J Clin Pathol; 2009 Oct; 62(10):903-7. PubMed ID: 19783718
    [TBL] [Abstract][Full Text] [Related]  

  • 29. IgVH mutational status and clonality analysis of Richter's transformation: diffuse large B-cell lymphoma and Hodgkin lymphoma in association with B-cell chronic lymphocytic leukemia (B-CLL) represent 2 different pathways of disease evolution.
    Mao Z; Quintanilla-Martinez L; Raffeld M; Richter M; Krugmann J; Burek C; Hartmann E; Rudiger T; Jaffe ES; Müller-Hermelink HK; Ott G; Fend F; Rosenwald A
    Am J Surg Pathol; 2007 Oct; 31(10):1605-14. PubMed ID: 17895764
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pattern of T-cell receptor delta gene rearrangement by Southern blotting and polymerase chain reaction technique in Hong Kong Chinese patients with non-T-cell hematological malignancies.
    Chan DW; Liang R; Kwong YL
    Hematol Oncol; 1996 Jun; 14(2):57-66. PubMed ID: 8876635
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Concurrent detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukaemia by flow cytometry and real-time PCR.
    Kerst G; Kreyenberg H; Roth C; Well C; Dietz K; Coustan-Smith E; Campana D; Koscielniak E; Niemeyer C; Schlegel PG; Müller I; Niethammer D; Bader P
    Br J Haematol; 2005 Mar; 128(6):774-82. PubMed ID: 15755280
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Immunoglobulin super-gene family and its related genes in detecting MRD in ALL].
    Dong S; Kuang S; Huang W
    Zhonghua Yi Xue Za Zhi; 1996 Oct; 76(10):742-6. PubMed ID: 9275514
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Relationship between DNA methylation and expressions of p57kip2 in hepatocellular carcinoma].
    Zhao JZ; Zhang ZJ; Shen LJ; Cheng RC; Zhang HX; Qian ZY
    Zhonghua Gan Zang Bing Za Zhi; 2009 Sep; 17(9):703-4. PubMed ID: 19785964
    [No Abstract]   [Full Text] [Related]  

  • 34. Minimal residual disease detection by flow cytometry and PARR in lymph node, peripheral blood and bone marrow, following treatment of dogs with diffuse large B-cell lymphoma.
    Aresu L; Aricò A; Ferraresso S; Martini V; Comazzi S; Riondato F; Giantin M; Dacasto M; Guadagnin E; Frayssinet P; Rouquet N; Drigo M; Marconato L
    Vet J; 2014 May; 200(2):318-24. PubMed ID: 24698669
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical significance of PCDH10 promoter methylation in diffuse large B-cell lymphoma.
    Huang W; Xue X; Shan L; Qiu T; Guo L; Ying J; Lu N
    BMC Cancer; 2017 Dec; 17(1):815. PubMed ID: 29202805
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Methylation contributes to imbalance of PRDM1α/PRDM1bβ expression in diffuse large B-cell lymphoma.
    Zhang YW; Zhang J; Li J; Zhu JF; Yang YL; Zhou LL; Hu ZL; Zhang F
    Leuk Lymphoma; 2015; 56(8):2429-38. PubMed ID: 25487076
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Plasma DNA methylation of shp1 in patients with diffuse large B cell lymphoma].
    Chen X; Fu R; Wang Y; Song W; Ruan E; Qu W; Wang H; Wang G; Song J; Wang X; Wu Y; Xing L; Liu H; Li L; Guan J; Shao Z
    Zhonghua Yi Xue Za Zhi; 2014 Apr; 94(14):1071-5. PubMed ID: 24851890
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Possible Role of GADD45γ Methylation in Diffuse Large B-Cell Lymphoma: Does It Affect the Progression and Tissue Involvement?
    Barış İC; Caner V; Şen Türk N; Sarı İ; Hacıoğlu S; Doğu MH; Çetin O; Tepeli E; Can Ö; Bağcı G; Keskin A
    Turk J Haematol; 2015 Dec; 32(4):295-303. PubMed ID: 25912017
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Emerging Role of Minimal Residual Disease Testing in Diffuse Large B-Cell Lymphoma.
    Hu R; Winter A; Hill BT
    Curr Oncol Rep; 2019 Apr; 21(5):44. PubMed ID: 30941515
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epigenetic mechanisms of protein tyrosine phosphatase 6 suppression in diffuse large B-cell lymphoma: implications for epigenetic therapy.
    Witzig TE; Hu G; Offer SM; Wellik LE; Han JJ; Stenson MJ; Dogan A; Diasio RB; Gupta M
    Leukemia; 2014 Jan; 28(1):147-54. PubMed ID: 23979523
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.